Gene therapy with viral vectors has progressed to clinical trials. However, the localization of viral vector delivery to diseased target sites remains a challenge. We tested the hypothesis that an adenoviral vector could be successfully delivered by complexation with a specific antibody that is bound to a biodegradable matrix designed for achieving localized gene transduction. We report the first successful delivery system based upon antibody immobilization of virions in a type I collagen-avidin gel using a polyclonal biotinylated IgG specific for the adenovirus hexon. In vitro stability studies demonstrated retention of viral vector activity with antibody-complexed adenovirus collagen gel preparations, in comparison to loss of vector activity from collagen gels prepared with nonspecific biotinylated IgG. Cell culture investigations using this antibody-controlled release system for adenoviral vector transduction of rat aortic smooth muscle cells (A10) demonstrated a significantly more localized reporter expression (␤-galactosidase) compared with non-antibody-complexed controls. Herpes simplex thymidine kinase (HSVtk) adenoviral vectors were immobilized on avidin-collagen gels via this antibody-com-
Introduction
The use of viral vectors for gene therapy has progressed to clinical trials [1] [2] [3] [4] [5] [6] [7] [8] which, to date, have involved vector delivery through injection of a liquid suspension of viral particles. However, injection of virions yields inefficient localization of the vector at diseased target sites. This approach also permits distal spread of viral vectors, which contributes to the potential risk for dangerous systemic side-effects. The present study addresses these issues by reporting for the first time, a viral vector delivery system, based upon a matrix-immobilized antibody complexation of the viral vector.
Drug delivery involving polymeric matrices designed for sustained release of therapeutic agents is now a very broad field, encompassing both low molecular weight pharmaceuticals, 9, 10 and proteins and peptides. [11] [12] [13] [14] [15] In recent years, sustained release preparations for the deliv- plexation approach, and ganciclovir was added to rat smooth muscle cells (A10) in culture with the gels. With complexed HSVtk adenovirus, only cells either in contact with the viruscontaining gel or within 50 m were killed. By comparison, at the same adenovirus and ganciclovir dose, non-antibodycomplexed HSVtk adenoviral delivery with ganciclovir resulted in the death of virtually all cells. Myocardial gene transfer studies in pigs demonstrated significantly more efficient right ventricular adenoviral GFP expression with anti-hexon antibody-complexed matrix injections, compared with direct vector injections. Thus, our results show that matrix formulations based on antibody-complexation delivery of adenovirus resulted in site-specific localization of transgene expression that enhances the efficiency of therapeutic vector strategies and provides a potent means for localization, to avoid distal side-effects. This approach has therapeutic potential as an implantable preparation that through the means of antibody-complexation, can localize and optimize viral vector gene therapy. Gene Therapy (2001) 8, 659-667.
ery of antisense oligonucleotides [16] [17] [18] [19] [20] and plasmid DNA [21] [22] [23] [24] [25] have been shown to be both feasible and successful in experimental studies. Viral vectors have also been incorporated into microparticle sustained release systems that are formulated from polylactic polyglycolic acid, 26 and in separate studies, from collagen coacervates. 27 These delivery systems permit the sustained presence, but not localization of gene vectors in a region of administration, due to local biodegradation of the carrier formulation. However, these previously reported sustained release adenoviral preparations 26, 27 were not formulated to enable localization of the viral vector at the desired therapeutic target site, and thus transduction could be suboptimal due to unrestricted diffusion of either the virus or of the microparticle carrier system, with resulting unwanted transduction at distal sites. In the present study, we have approached viral vector delivery through the use of an aqueous-based biodegradable matrix containing an immobilized adenovirus antibody for the specific matrix binding, localization, and delivery of antibody-complexed adenoviral vectors.
We investigated the hypothesis that a viral vector delivery system could be formulated through antibody-mediated adenoviral binding within a biodegradable matrix, so that localized transduction would be enhanced, and regional efficiency optimized, compared with viral vector administration as a suspension in an aqueous solution. Thus, we pursued the following goals: (1) Formulation of collagen-based matrices for antibodymediated gene delivery of adenoviral vectors. (2) Investigations of these matrices as adenoviral vector delivery systems in cultured cells in order to characterize in vitro the mechanisms of localization of transduction. (3) Studies of antibody-mediated delivery of a therapeutic adenoviral vector encoding herpes simplex virus thymidine kinase (HSVtk), with co-administration of ganciclovir, in cell culture, to assess the therapeutic advantages of localization compared with controls. (4) In vivo administration of the anti-hexon antibody-adenovirus complex in collagen gels, comparing injections of the complex with direct administration of the same dose of adenovirus in a series of pig right ventricular myocardial injection studies, using a green fluorescent protein (GFP) adenovirus to assess differences in expression.
Results
Collagen gels were readily formed with type I collagen and NeutrAvidin in a 1:1 ratio, and gelation occurred at 37°C in less than half an hour, yielding gels which were robust in their stability and ease of handling. These collagen gels, when formulated with biotinylated-IgG mixed in bulk with the NeutrAvidin, were found to solidify somewhat more rapidly and to be physically more resistant to tearing with handling than were gels without avidin-biotinylated antibody immobilization. We first wished to determine the importance of avidin-biotin interaction on immobilization of the antibody. Application of a FITC-labeled second antibody against the biotinylated primary antibody revealed intense fluorescence in the gels containing NeutrAvidin (Figure 1a ). Barely detectable fluorescence was seen in the controls that did not contain the NeutrAvidin (Figure 1b) .
In vitro stability studies demonstrated retention of viral vector activity with hexon-specific antibody-complexed adenovirus in collagen-avidin gel preparations, in comparison to virtually complete diffusion of adenoviral vectors from collagen-avidin gels prepared with nonspecific biotinylated IgG. In these experiments, GFP-adenovirus was enclosed in collagen-avidin gels with either biotinylated anti-hexon IgG or nonspecific biotinylated IgG. Gels were incubated at 37°C in phosphate buffered saline (PBS), and sampled at intervals (Figure 2 ) for eluted virus, and gel removal to examine transduction efficiency in A10 cell cultures. Antihexon-IgG gels retained 70% or more of their original transduction capability for up to 10 days (Figures 2a), and GFP transduction of rat arterial smooth muscle cells (A10) was highly localized ( Figure  2b ) to cells growing on the collagen gels containing the anti-hexon antibody. Nonspecific IgG gels demonstrated a rapid decline in transduction activity with less than 5% transduction capability remaining by 10 days (Figure 2c) , and GFP transduction of A10 cells was not localized to cells growing on these sampled gels even at 5 days (Figure 2d ). By 15 days under simulated physiologic conditions, collagen-avidin gels began to physically deteriorate, thereby explaining the loss of antibody-complexed viral vector by this time. A series of cell culture studies compared the various formulation components, and demonstrated nearly exclusive localization of ␤-galactosidase transduction to the collagen-avidin matrix in the anti-hexon antibody derivatized preparations (Figure 3a) . In general, our cell counting data (summarized in Figure 3d ) revealed that antibody-complex delivery of adenovirus vector over 72 h resulted in significantly more localized transduction (P р 0.001, Figure 3a vs Figure 3c ), compared with controls. Of interest is the limitation of adenovirus elution from the collagen matrix due to nonspecific biotinylated IgG combined with avidin in the collagen matrix (Figure 3b ). This is likely due to avidin-biotin affinity causing effectively crosslinking of the collagen matrix. Thus, the mechanism of viral egress from the anti-hexon matrix is due to both specific immunobinding of adenovirus, and avidin-biotin crosslinking also limiting viral vector release. Nevertheless, the effects of the specific antibody binding were significantly greater than those noted with a b c d
Figure 2 Retention of antihexon antibody-complexed adenovirus by specific antibody binding within collagen-avidin gels. (a) Slow release over time of anti-hexon antibody complexed GFP-adenovirus, with gradual elution of antihexon-complexed adenovirus into phosphate buffered saline incubation media at 37°C. (b) Fluorescence micrograph (FITC) of GFP-positive cells localized to cells on a gel with anti-hexon antibody complexed adenovirus after 10 days of prior pH 7.4 incubation (200×). (c) Rapid loss of GFP adenovirus included within a collagen-avidin gel containing non-specific biotinylated IgG. (d) FITC micrograph of GFP-positive cells transduced in a non-localized manner following 5 days of exposure to collagen-avidin gel containing GFP adenovirus with non-specific biotinylated IgG. (Arrows indicate matrix edge in b and d, 200×).
a nonspecific biotinylated IgG (P Ͻ 0.01, Figure 3d ).
Other control experiments incorporating adenovirus into the bulk of a collagen gel without the presence of antibody revealed apparent free diffusion of the virus out of the gel, as widespread transduction was seen throughout the culture plate ( Figure 3c ). Direct addition of 10 7 p.f.u. of ␤-galactosidase adenovirus to our A10 cell cultures also resulted in widespread transduction, comparable to that noted with the non-antibody-containing collagen gel (data not shown). As expected, a non-virus-containing collagen gel, with the adenovirus-specific IgG, did not demonstrate any ␤-galactosidase positive staining (results not shown).
Herpes simplex thymidine kinase (HSVtk) adenoviral vectors (10 7 p.f.u.) were immobilized on avidin-collagen gels via the anti-hexon antibody approach. Ganciclovir was added to the cultures (10.0 g/ml). Arterial smooth muscle cells were cultured in the presence of this viral delivery system. All cells both growing on the gels and within 50 m were obviously nonviable after 48 h ( Figure  4c ). However, the remainder of the cells in the culture Gene Therapy plates appeared to be viable and actively proliferating. In control comparisons, at the same ganciclovir and viral vector dose, non-tethered adenoviral delivery, using avidin-collagen gels with nonspecific biotinylated IgG, with added ganciclovir resulted in the death of virtually all cells in these cultures (Figure 4b ).
Adenoviral vector delivery to porcine right ventricle was investigated, comparing injection of the anti-hexonadenovirus collagen gel with direct injection of the same viral dose. The results of these studies showed a widespread, uniform pattern of expression with high efficiency transduction with the anti-hexon collagen-avidin gel (Figure 5b and c) . By comparison, direct adenoviral administration resulted in a needle-track pattern of gene expression, with significantly less efficient gene transfer than found with the anti-hexon results ( Figure  5a and c). An inflammatory infiltrate was noted with both methods of vector delivery (Figure 5d and e), but with more extensive monocytic infiltration with the anti-hexon gel, likely due to more widespread adenoviral transduction. Biodistribution studies revealed PCR detectable GFP DNA only in lung samples from all but one of the animals in the anti-hexon collagen matrix group. The direct adenoviral injection group also showed the presence of GFP DNA only in the lung in all but one of these pigs. Other sampling sites, liver, kidney, and left ventricle were negative for the presence of GFP DNA. Thus, these data indicate that although the anti-hexon formulation provides more efficient and widespread gene transfer than direct injection, nevertheless distal spread to lung is comparable, and is likely due to coronary venous uptake of nonlocalized adenoviral viral vector.
a c b d

Figure 3 Antihexon antibody-complexed adenovirus within a collagen-NeutrAvidin matrix yields matrix-localized transduction compared with controls. (a) Adenovirus with anti-hexon biotinylated antibody-NeutrAvidin in a collagen matrix (arrows indicate matrix edge) demonstrating transduction restricted to matrix (X-gal, 200 ×). (b) Adenovirus release and expression from a matrix with nonspecific biotinylated IgG plus biotin and collagen, showing notably more expression beyond the matrix than with noted with anti-hexon IgG per A (X-gal, 200 ×). (c) Adenovirus within a collagen matrix without specific antibody complexation (arrows indicate matrix edge) demonstrating widespread transduction (X-gal, 200 ×). (d) Percentage of rat arterial smooth muscle cells (A10) transduced (in a,
Discussion
The localization of transduction with antibody complexed adenoviral vector may be attributed to several mechanisms. Antibody-antigen binding coupled with avidin-biotin affinity resulted in vector localization within the matrix with little free dissociation of the bound adenovirus in PBS incubations, suggesting only minimal free diffusion of antihexon antibody-complexed virus. However, our cell culture studies demonstrate that the mechanism of adenoviral delivery from the antihexon matrix is due in part to both specific immunobinding of adenovirus, and avidin-biotin crosslinking of the collagen matrix (see Figure 3) . Thus, a likely scenario for the fate of matrix-incorporated virus includes early elution of a small fraction of incompletely complexed virus, with some limitation of vector diffusion due to avidinbiotin crosslinking. However, the anti-hexon complexed vector is essentially immobilized, and thereby involved in gene transfer to cells specifically invading and mediating biodegradation of the matrix followed by endocytosis of antibody-virus complexes and intracellular processing leading to gene expression. Although only arterial smooth muscle cells were investigated in the in vitro portion of this study, adenoviral vectors transduce a broad range of cell types, in vivo and in vitro, and thus it is likely that the antibody-complexation delivery system reported here would be useful for a wide variety of gene therapy investigations. Antibody immobilization and control of release of viral vectors permits localization, which should hypothetically enhance local efficacy, as well as minimize spread of the virus to distal sites. This aspect of greater control of viral gene vector delivery has a number of significant features that could be modulated to enhance site-specific therapy. For example, binding affinity could be made greater through the use of monoclonal antibodies with enhanced specificity. Furthermore, release of the antibody-virus complex could also be controlled through the use of enzymatically cleavable and/or hydrolyzable linkers. 28 While the avidin-biotin complex that we used is quite stable, we could have chosen to use a disulfide mechanism for antibody immobilization, with a disulfide linking entity that could be hydrolyzed through either biodegradation or local controlled release of a disulfide reducing agent. 29 Controlled localized gene delivery at the site of administration could also be achieved using multiple different viral vectors, with different antibody binding systems and/or a program of monoclonal antibodies, in order to stage and design delivery of a therapeutic genetic modification that would achieve the desired optimal effect. Anti-hexon adenoviral matrices were also observed to deliver adenoviral vectors efficiently in porcine myocardial gel injection studies. Myocardial gene transfer with anti-hexon matrix administration was more efficient, and more locally diffuse, than with direct adenoviral injections. This is likely due to matrix retention of vector in the myocardium both at the site of injection and in proximal regions in which the anti-hexon gel diffused. In comparison, the needle track pattern of gene expression with direct vector injection is probably due to both limited transduction to the regions of highest concentration of adenovirus, and a rapid run-off of non-complexed vector before cellular uptake. Biodistribution results demonstrated PCR detectable vector DNA in the lungs (but not other organs) of animals receiving the anti-hexon matrix. While these results are encouraging from the point of view of sparing the liver and other sites, they indicate incomplete site specificity of the anti-hexon formulation. Recent results from our laboratory 30 using a disulfide immobilized anti-knob F(ab)Ј 2 indicate no distal spread of vector, and represent a more ideal formulation in terms of safety and toxicity concerns.
The HSVtk results (Figure 4 ) are of potential importance to several therapeutic areas. By restricting HSVtk activity, it is possible to limit the potent bystander effect of ganciclovir activation, thereby enhancing this promising strategy in therapeutic areas where it has already shown efficacy, but with toxicity. For example, therapy of solid tumors, many of which have been successfully treated with HSVtk and ganciclovir 31, 32 could be more optimally treated with the use of our anti-hexon antibody adenoviral vector delivery system. HSVtk with co-administration of ganciclovir has also been demonstrated to inhibit the development of experimental arterial restenosis effectively following angioplasty.
33,34 Thus, stentbased delivery of adenoviral vectors using the antibody complexation approach reported here could also hypothetically facilitate prevention of in-stent restenosis, via use of the HSVtk ganciclovir approach demonstrated in our studies.
Although no others have reported the use of antibodycomplexed adenovirus within matrices, collagen sponges with absorbed adenoviral vectors have been investigated in wound healing studies. 35 These investigations demonstrated enhanced localized wound healing using a PDGF adenoviral vector. This approach is comparable to the control formulations we investigated (Figure 3b, c and d) , in which adenovirus was passively incorporated into a collagen matrix (without a vector-specific antibody), and had significantly less localized expression than the antihexon-complexed formulation. However, for cutaneous therapeutic applications, where systemic spread of vector from a wound site is a lesser concern, a collagen matrix approach without antibody-mediated site specificity is likely to be acceptable for selected indications from a safety and efficacy standpoint.
The therapeutic implications of our virus-controlled release delivery system could have a significant impact on a number of different fields. In wound healing, the collagen-antibody configuration that we used could lend itself to utility as a site-specific adenovirus-containing wound dressing, that could be used in immunocompromised patients. In cardiovascular surgery, it is also conceivable that this delivery system could function as part of a collagen-coated vascular graft or prosthetic valve, with a collagen-based antibody-complex viral vector delivery system within the prosthetic valve's components (cusps, stent, sewing ring), to enable optimal healing. In fact, virtually any surgical implant can be converted into a partially bioactive device using an antibody-bound and immobilized viral vector to improve the outcome of the implant. An injectable and gellable form of our antibodybinding system could have a number of important therapeutic uses. A myocardial gene therapy strategy based on this approach could potentially be used for myocardial revascularization, or even for local therapy of cardiac arrhythmias to modify abnormal conduction pathways through overexpression of selected ion channels. An injectable gellable preparation could also be used to coat mucous membranes, such as the tracheal-bronchial epithelium, thereby localizing viral vectors and modifying the respiratory epithelium in diseases such as cystic fibrosis. Another potential use could be intrauterine injection, with ultrasound guidance during the course of fetal surgery to achieve local gene therapy modifications of diseased fetal organs.
Tissue engineering also offers a number of important experimental possibilities to explore the importance of antibody-controlled localized viral gene vector delivery. A tissue-engineered scaffold typically consists of a synthetic, and biodegradable matrix, on to which cells can grow for the regeneration of a diseased organ or injured tissue. It may be advantageous to build in regional, antibody-controlled virus-based gene delivery, in order to predetermine the type of cellular response and mechanotransduction that would be most desirable in a tissue engineered implant. Such complex tissue assembly could be modeled in vitro using antibody complexation technology to transfect adjacent cell populations differentially and study their interactions.
It is concluded that: (1) adenoviral vector delivery has been successfully achieved for the first time using antiadenovirus antibodies to complex the vector within a collagen matrix. (2) Proximal localization of viral vector transduction to the anti-hexon antibody-adenovirus-containing gel has been demonstrated in rat arterial smooth muscle cell cultures. (3) Antibody-based adenoviral vector was also shown to deliver HSVtk effectively and thereby to result in site-specific localization of ganciclovirmediated cell killing. The therapeutic implications of these results are of particular importance to the chemotherapy of solid tumors, and post-angioplasty restenosis. (4) More efficient in vivo myocardial transduction was noted with anti-hexon antibody complexed adenoviral vector in collagen matrices, compared with direct injection of adenovirus.
Materials and methods
Type I bovine dermal collagen, Vitrogen 100, was obtained from the Collagen Corporation (San Francisco, CA, USA). NeutrAvidin was obtained from Pierce (Rockford, IL, USA). A polyclonal goat anti-adenovirus hexon biotinylated IgG preparation was purchased from Biodesign International (Kennebunk, ME, USA). A nonspecific goat biotinylated immunopure IgG was obtained from Pierce. A rabbit anti-goat IgG FITC-conjugated preparation was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
A type 5 adenovirus (H5.010) ␤-galactosidase replication defective adenovirus was provided by the Vector Core of the Institute for Human Gene Therapy at the University of Pennsylvania (Philadelphia, PA, USA). An identical vector encoding for the green fluorescent protein (GFP) was also used. A therapeutic adenoviral vector encoding for herpes simplex virus thymidine kinase (HSVtk) (CMV promoter) was provided by Dr Elizabeth Nabel of the University of Michigan. The viral vector constructs were first-generation adenoviruses, with the reporter genes under the control of the cytomegalovirus (CMV) promoter, with E1 and E3 deletions. A10 cells (rat aortic smooth muscle cells) were obtained from the American Type Culture Collection (Manassas, VA, USA).
Avidin-collagen gels were prepared using neutralized collagen, buffered in HEPES (pH 7.4, 0.05 m). Following neutralization, NeutrAvidin was added to the collagen in a one to one ratio (weight ratio) followed by incubation at 37°C for 45 min, when complete gelation occurred for use in cell culture experiments. The amount of NeutrAvidin used was empirically determined, based on using maximal amounts (to ensure complete biotin-avidin interactions), while not compromising 37°C gelation properties. Biotinylated-antihexon antibody-virus complexes were performed by incubating 0.16 mg of Ig with 10 9 p.f.u. of adenovirus for 30 min at 37°C. It was observed that lesser amounts of the biotinylated antihexon IgG gave poorer localization results, and greater amounts did not result in significantly greater levels of localization. Bulk preparations of the collagen-avidinbiotinylated antibody-adenovirus were prepared by combining the 1:1 collagen-NeutrAvidin mixture with the antibody-virus complex.
For experiments involving FITC-labeled second antibody detection to detect IgG immobilization, a 1:50 dilution of the secondary antibody was incubated for 1 h at 37°C with the NeutrAvidin-containing gels, formulated with either nonbiotinylated IgG, or biotinylated anti-hexon IgG, followed by copious potassium phosphate buffered (0.05 m, pH 7.4) saline rinses. The gels were then examined under a fluorescence microscope (Nikon Eclipse E800; Nikon, Tokyo, Japan) for the detection of bound FITC-label, thus demonstrating specific association of the adenovirus-binding antibody.
In vitro stability studies were carried out to assess retention of viral vector activity with hexon-specific antibody-complexed adenovirus collagen-avidin gel preparations, in comparison with adenoviral vectors incorporated in collagen-avidin gels prepared with nonspecific biotinylated IgG. In these studies, gels loaded with 10 7 p.f.u. of GFP adenovirus were incubated in phosphate buffered saline (pH 7.4), and sampled periodically to assess viral vector activity. Sampling included both the incubation buffer, and removal of gel samples to assess viral vector activity. Buffer aliquots or gels were placed in A10 cell cultures (10 5 cells), which were assessed after 72 h for transduction as detailed below, after cover slipping with 4-6 diamidino-2-phenylindole (DAPI), using Vectamount Vectashield Fluorescent Mounting Medium (Vector Laboratories, Burlingame, CA, USA). Data were Gene Therapy expressed as percentages of cells transduced on the gels themselves, or for the buffer time-point samples, as percentages of cells transduced per cell culture plate.
Cell culture experiments used adenovirus-containing collagen matrices formulated as above. Typically, 10 5 A10 cells (rat arterial smooth muscle) were added to a culture plate containing the collagen matrix (100 l volume) on a glass cover slip. The adenoviral dose used was 10 7 p.f.u. per 35 mm cell culture plate. ␤-Galactosidase was detected as follows: 4% paraformaldehyde (pH 7.4) fixation was followed by rinsing with 2 mm MgCl 2 (pH 7.4). X-gal staining solution was then added to each culture plate, and an overnight incubation at 37°C followed. 36 Then, the staining solution was removed and the cells were rinsed with copious amounts of PBS. The cells were fixed with paraformaldehyde once again before being stored in PBS at 4°C and cover-slipped using 4-6DAPI.
Transduction efficiency was studied in the cell culture experiments by direct counting of ␤-galactosidase-positive cells or GFP-positive cells, in comparison to total cell counts in the regions of interest using DAPI fluorescent stain, specific for cell nuclei. For the purposes of regional comparison in ␤-galactosidase studies, three proximal fields were counted for each of the three replicate experiments, and three distal fields were counted for each of three replicates. In addition, three replicate fields were counted over the surface of each 100-l collagen gel (2-4 mm diameter) in order to ascertain the extent of transduction of cells invading the gel. Cells counts were obtained using the 4 × optical of a Nikon Eclipse E800 (Nikon, Inc., Tokyo, Japan) microscope. Proximal fields were defined as regions from the margin of the virus delivery matrix extending 100 m into the periphery. Distal fields were counted between 100 m from the edge of the matrix to the edge of the glass cover slip (2.2 cm diameter) on which the collagen gel had been mounted. Data were expressed as the means of percent transduced per field in each region for each of the triplicate experiments. The mean cells counted per non-matrix region ranged from 512-769 ± 26.2-47.0, standard error. The means cells counted per matrix field region ranged from 127-171 ± 47.1-48.9, standard error. Statistical differences between groups and the relevant controls were assessed using the Student's t test.
HSVtk adenoviral vectors (10 7 p.f.u. per gel) were immobilized on avidin-collagen gels via the anti-hexon antibody-complexation approach, and ganciclovir (10.0 g/ml) was added to the cultures. Arterial smooth muscle cells (A10) were cultured in the presence of this viral delivery system. Cell morphology and viability was assessed after 48 h of ganciclovir exposure. Cells were stained with Coomassie stain (BioRad, Hercules, CA, USA) and viewed under an inverted microscope. Regions of interest included cell ingrowth into the collagen gel, cells growing proximal to the gel, and distal cell growth activity.
An in vivo study examined differences in GFP adenovirus transduction comparing antihexon-complexation to direct ventricular injections in pigs. Animal use was approved by the Institutional Committee for the Use and Care of Animals of the Children's Hospital of Philadelphia. Under general anesthesia (isofluorane), pigs (male, Yorkshire swine, 3 months of age) were subjected to a right thoractomy, and the right ventricular epicardium was exposed. Using a 30-gauge needle and syringe, pigs were administered either the GFP-antihexon NeutrAvidin-collagen complex or GFP-adenovirus. Seven pigs were administered GFP-adenovirus (10 8 p.f.u.) within an anti-hexon biotin-avidin-collagen gel, using a right ventricular injection (0.1 ml, administered with a 30-gauge needle). A control group of eight animals were administered GFP-adenovirus (10 8 p.f.u.) suspended in sterile water as a direct right ventricular injection. The animals were killed after 1 week and the injected myocardial sites were retrieved for analysis of gene expression using frozen sections followed by fluorescence microscopy, and overall morphology with hematoxylin and eosin (H&E) staining. Morphometric assessment of gene expression was performed using the following methodology: the total number of GFP-expressing cells was directly counted in each 200 × DAPI-mounted field assessed, and the total number of DAPI-stained nuclei for each section was then counted using NIH Image software. Data are expressed as the percent transduced per 200 × field, ± standard error. Samples of left ventricular myocardium, lung, liver, and kidney were also retrieved and snap frozen on dry ice for PCR analyses for GFP DNA. The GFP primers used for these studies were 5Ј-CGG ATC CTC TAG AGT CGA C-3Ј (forward) and 5Ј-GGC TGC TGC AAA ACA GAT AC-3Ј (reverse). Following extraction of genomic DNA, samples were subjected to 35 cycles and the PCR products run on agarose gel electrophoreses with ethidium bromide fluorescence detection.
